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Abstract
Statins can decrease lowering level of Low-Density Lipoprotein 
Cholesterol (LDL-C), and have been effective for prevention 
of Atherosclerotic Cardiovascular Disease (ASCVD). Lipid-
Lowering Therapy (LLT) has been prevalent, but some cases 
develop statin intolerance. Cases with statin intolerance may 
show Statin-Associated Muscle Symptoms (SAMS). SAMS 
includes various clinical manifestations, such as general malaise, 
mild weakness, muscle pain and cramps with about 5-10% of 
incidence in clinical practice. European Atherosclerosis Society 
(EAS) consensus panel included three SAMS types, which are 
myalgias, myositis and rhabdomyolysis. There is a proposal of 
algorithm for the management of SAMS with several stages such 
as genesis, exams, diagnosis, evaluation and management. As 
non-statin based therapies, ezetimibe and Proprotein Convertase 
Subtilisin/Kexin type 9 (PCSK9) inhibitors can be added and 
applied.
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associated muscle symptoms; Statin intolerance Statins have the function of lowering level of LDL-C, and have 
been effective in the primary and secondary prevention of ASCVD. 
Then, statins have been important to continue Lipid-Lowering Therapy 
(LLT), and given to many patients for years [9]. Among those cases 
with provided statins, some cases show "statin intolerance". It is defined 
as "an adverse event by oral administration of statins, which causes 
unacceptable disorders in daily life, leading to drug discontinuation 
and dose reduction". It has two situations. One is complete intolerance 
which is difficult to continue at any given dose of any statin, and another 
is partial intolerance which is found at certain doses of a particular 
statin formulation.
Cases with statin intolerance may show Statin-Associated 
Muscle Symptoms (SAMS) [10]. The most common features of SAMS 
are in the following: i) developed symptoms within 4-6 weeks after 
starting statin preparation, ii) involvement of gluteus, flexor thigh, calf, 
proximal brachial muscle, etc. iii) bilateral symmetry. iv) disappearance 
by discontinuing the agent for 2-4 weeks. If the same symptoms are 
reproduced within 4 weeks after re-administration, it is diagnosed that 
the possibility of SAMS would be high. In such case, changing to other 
statin products or medications are considered. If the serum Creatine 
Kinase (CK) value is less than 1000 IU/L, the numerical value itself is 
not so particularly important but the subjective symptoms should be 
prioritized for judgment.
Commentary
Across the world, Non-Communicable Diseases (NCDs), 
lifestyle-related diseases and metabolic syndrome have been in focus 
for clinical practice [1]. They include diabetes, obesity, dyslipidemia, 
hypertension and others. These diseases may develop Atherosclerotic 
Cardiovascular Disease (ASCVD) [2]. Especially, the possibility of 
ASCVD may be increased by the elevated values of glycosylated 
hemoglobin (HbA1c) and Low-Density Lipoprotein Cholesterol 
(LDL-C) [3].
Furthermore, American College of Cardiology and American 
Heart Association (ACC–AHA) presented the comment for primary 
prevention of CVD [4]. Both associations proposed the clinical 
guidelines for management of lipids [5]. Using the guidelines, beneficial 
management for prevention of ASCVD will be recommended.
Value of LDL-C has been reported to show direct relationship 
to the risk of ASCVD [6]. Consequently, LDL-C was known as lower 
is better. When LDL-C becomes lower each 39 mg/dL, cardiovascular 
event decreases by 22% associated with mortality by 10% [7]. About 30 
thousand cases on statin therapy showed the reduction level of LDL-C 
as 39% [8].
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SAMS has relevant adverse effect for causing discontinuation 
of statin meds, leading to subsequently elevated cardiovascular events 
[9]. The incidence of SAMS seems to be about 5% to 10% in actual 
clinical practice. SAMS includes various clinical manifestations, 
such as general malaise, mild weakness, muscle pain and cramps 
[11]. It rarely causes severe rhabdomyolysis, which needs emergency 
treatment. SAMS usually shows muscle pains (more than 80%) with 
and without mild elevation of CK. For patients with SAMS, clinical 
management includes two steps. The first is discontinuation of statins, 
and the second is reintroduction of low dose of statin combined 
with non-statins. Non-statins mean ezetimibe at first, and addition 
of alirocumab or evolucumab if needed. This protocol may bring 
meaningful achievement of LDL-C reductions in most cases [12].
Regarding SAMS, clinical spectrum has been heterogeneous, 
in which it ranges from mild fatigue, muscle pain, cramp to life 
threatening rhabdomyolysis. European Atherosclerosis Society 
(EAS) proposed EAS consensus panel that there are three definition 
of SAMS types [13]. They are i) myalgias: muscle symptoms with 
normal to mild increased CK, ii) myositis: muscle symptoms plus 
CK value (upper limit of normal (ULN) x 10<), iii) rhabdomyolysis: 
muscle symptoms plus CK value (ULN x 40<) plus renal failure [14].
There is a proposal of algorithm for the management 
of SAMS [12]. It includes several stages as follows: i) genesis: 
exclusion of exacerbating factors such as drug interaction, exercise, 
hypothyroidism, etc., ii) exams: laboratory data of CK, TSH, 
creatinine, vitamin D, etc., iii) diagnosis: judgement for myalgias, 
myositis or rhabdomyolysis, iv) evaluation: assessment of symptoms 
severity and confirmation of statin safety, v) management: stop 
or continue statins, and follow CK and symptoms, vi) restart or 
not: decision medicine for statins, Ezetimibe or other option. This 
presents a therapeutic flow chart for SAMS, and some SMAS cases 
are possibly from vitamin D deficiency [15]. In such case, vitamin D 
replacement treatment would be reasonable [14].
There have been some recommended methods of LLT. As 
statin-based therapies, statins at low dose with long half-lives are 
provided. For example, atorvastatin 5 mg is given on alternate days, or 
rosuvastatin 5 mg is given 1-3 times per week. Using these methods, 
LDL-C is expected to be reduced by 25-35% [16]. After reassessment 
for tolerating this approach in 4-6 weeks, statin and ezetimibe 10mg 
daily can be added.
In contrast, as non-statin based therapies, we can apply 
ezetimibe and Proprotein Convertase Subtilisin/Kexin type 9 
(PCSK9) inhibitors, which are alirocumab and evolocumab [17,18]. 
Those show clinical efficacy by adding background statin therapy in 
cases with CVD [18,19].
Concerning ezetimibe, it was firstly recognized non-statin 
medicine for statin intolerance, which was proposed by European 
Guidelines for the management of dyslipidemias [20]. It can reduce 
LDL-C by 15-20% by daily 10mg, and does not develop muscle 
symptoms. Combined therapy of intermittent low statin and 
ezetimibe may decrease LDL-C by 40-45% [20].
Regarding PCSK9 inhibitors, they are novel class of 
hypolipidemics as fully human antibodies that can lower LDL-C 
value to large extent (approximately less than 60%) [21]. Some 
studies enrolling patients intolerant for more than 2 statins showed 
the results that more than 80% cases could tolerate PCSK9 inhibitors 
with no muscular symptoms [22].
In summary, the management for SAMS patients would be a 
significant challenge in the clinical practice. It is a strategic approach 
associated with careful evaluation, reassurance of the case, diagnosis, 
and gradual restart of low statin amount or other strategy combined 
with non-statins. This algorithm may bring most patients to tolerate 
statins, where there are some options of combined with non-statin LLT 
(ezetimibe±PCSK9 inhibitors) leading to the reduction of LDL-C.
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